{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:15:21Z","timestamp":1794971721418,"version":"4.9.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To report real-life data on rituximab retention rate as an indicator of safety and efficacy in a multicentric national cohort of systemic sclerosis patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SSc patients treated with rituximab and followed for at least 36\u2009months were included, clinically characterized and longitudinally monitored. A competing risk analysis with sub-hazard ratio (sHR) definition was performed to explore the clinical variables linked to specific cause of rituximab discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One-hundred and fifty-two SSc-patients [mean age 47.3\u2009(12.3)\u2009years; females 79.6%; diffuse disease 77.6%; anti-topoisomerase-I positivity 63.2%] were evaluated over a median (interquartile range) time of 3.3 (1.7\u20135.0) years. The primary indications for rituximab were interstitial lung disease (38.8%), worsening skin fibrosis (36.8%) and arthritis (13.8%); 138 patients (90.8%) received more than one rituximab course. The 5-year rituximab retention rate was 59.9% (44.6\u201364.7%). Clinical response was the most common reason for rituximab discontinuation [5.7; 95% CI: (3.7\u20138.4) per 100 patient-years] and was associated with a shorter disease duration (sHR 0.8; 95% CI: 0.7, 0.9), anti-topoisomerase-I negativity (sHR 0.4; 95% CI: 0.2, 0.9), previous digital ulcers (sHR 2.6; 95% CI: 1.1, 6.2) and no history of arthritis (sHR 0.3; 95% CI: 0.1, 0.8). Treatment failure was the second cause of rituximab discontinuation [3.7 (95% CI: 2.2, 6.0) per 100 patient-years] and was associated with anti-centromere antibody positivity (sHR 2.8; 95% CI: 1.1, 7.4) and anti-topoisomerase-I negativity (sHR 0.2; 95% CI: 0.1, 0.6). Adverse events (AEs) were the less common cause of discontinuation [3.1 (95% CI: 1.7, 5.2) per 100 patient-years], associated with limited cutaneous subset (sHR 3.4; 95% CI: 1.2, 9.7) and previous mycophenolate mofetil treatment (sHR 4.5; 95% CI: 1.2, 16.3).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Rituximab is a safe and effective treatment in SSc: clinical response emerged as the primary reason for rituximab discontinuation, and AEs had a limited impact on treatment persistence. The identification of specific disease features associated with a response to rituximab will be useful in the management of SSc-patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae280","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:41:59Z","timestamp":1715758919000},"page":"1284-1291","source":"Crossref","is-referenced-by-count":10,"title":["Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-7714","authenticated-orcid":false,"given":"Giacomo","family":"De Luca","sequence":"first","affiliation":[{"name":"Scleroderma Unit, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-105X","authenticated-orcid":false,"given":"Enrico","family":"De Lorenzis","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-3794","authenticated-orcid":false,"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[{"name":"Scleroderma Unit, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-4462","authenticated-orcid":false,"given":"Fabio","family":"Cacciapaglia","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, DiMePRe-J University of Bari , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1549-8852","authenticated-orcid":false,"given":"Nicoletta","family":"Del Papa","sequence":"additional","affiliation":[{"name":"Scleroderma Clinic, ASST Gaetano Pini-CTO , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Zanatta","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Padova University Hospital , Padova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Air\u00f2","sequence":"additional","affiliation":[{"name":"Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-6866","authenticated-orcid":false,"given":"Maria Grazia","family":"Lazzaroni","sequence":"additional","affiliation":[{"name":"Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0041-3695","authenticated-orcid":false,"given":"Dilia","family":"Giuggioli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia , Modena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3196-1336","authenticated-orcid":false,"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital , Rozzano,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Alonzi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Stano","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, DiMePRe-J University of Bari , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Binda","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Padova University Hospital , Padova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Moccaldi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Padova University Hospital , Padova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tonutti","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital , Rozzano,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Scleroderma Clinic, ASST Gaetano Pini-CTO , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Batani","sequence":"additional","affiliation":[{"name":"Scleroderma Unit, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlando","family":"Natalello","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, DiMePRe-J University of Bari , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[{"name":"Scleroderma Unit, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Scleroderma Unit, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Laura","family":"Bosello","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2025030500175714400_keae280-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2025030500175714400_keae280-B2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2025030500175714400_keae280-B3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2025030500175714400_keae280-B4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025030500175714400_keae280-B5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2025030500175714400_keae280-B6","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"2025030500175714400_keae280-B7","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025030500175714400_keae280-B8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500175714400_keae280-B9","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025030500175714400_keae280-B10","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s10067-021-05698-4","article-title":"Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis","volume":"40","author":"Moradzadeh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025030500175714400_keae280-B11","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1093\/rheumatology\/keaa136","article-title":"Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study","volume":"59","author":"Campochiaro","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500175714400_keae280-B12","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025030500175714400_keae280-B13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025030500175714400_keae280-B14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025030500175714400_keae280-B15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/23971983211053246","article-title":"Primary systemic sclerosis heart involvement: a systematic literature review and preliminary data-driven, consensus-based WSF\/HFA definition","volume":"7","author":"Bruni","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"key":"2025030500175714400_keae280-B16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025030500175714400_keae280-B17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimal clinically important differences for the modified rodnan skin score: results from the scleroderma lung studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025030500175714400_keae280-B18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2397198318783926","article-title":"An interim report of the scleroderma clinical trials consortium working groups","volume":"4","author":"Baron","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"2025030500175714400_keae280-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2025030500175714400_keae280-B20","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"2025030500175714400_keae280-B21","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ard.2005.037333","article-title":"Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?","volume":"64","author":"M\u00e4kinen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025030500175714400_keae280-B22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025030500175714400_keae280-B23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: french retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025030500175714400_keae280-B24","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: a possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2025030500175714400_keae280-B25","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s10067-021-05733-4","article-title":"The target on B cells in Systemic Sclerosis: a \"midsummer dream\" to extinguish inflammation and prevent early disease progression to fibrosis","volume":"40","author":"De Luca","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025030500175714400_keae280-B26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13075-018-1569-0","article-title":"Characterization of inflammatory cell infiltrate of scleroderma skin: b cells and skin score progression","volume":"20","author":"Bosello","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025030500175714400_keae280-B27","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025030500175714400_keae280-B28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500175714400_keae280-B29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s42358-021-00170-y","article-title":"Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis","volume":"61","author":"de Figueiredo Caldas","year":"2021","journal-title":"Adv Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae280\/58394798\/keae280.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1284\/58394798\/keae280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1284\/58394798\/keae280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:19:09Z","timestamp":1741133949000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1284\/7673129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae280","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,5,15]]}}}